Literature DB >> 34601384

MiR-146a suppresses the expression of CXCR4 and alters survival, proliferation and migration rate in colorectal cancer cells.

Reyhaneh Afshar-Khamseh1, Arash Javeri2, Masoumeh Fakhr Taha3.   

Abstract

CXCR4 plays an important role in colorectal cancer (CRC) development and metastasis. Some previous studies have indicated CXCR4 as a therapeutic target in cancer. CXCR4 is known as a direct target of miR-146a. The present study aimed to investigate how exogenous induction of miR-146a affects CXCR4 gene and protein expression and also proliferation, apoptosis and migration of CRC cells. Transfection of Caco-2 and SW480 cells by a synthetic miR-146a mimic led to downregulation of CXCR4 expression at both gene and protein levels. It also downregulated expression of several miR-146a targets, including GSK3B, IRAK1, TRAF6, AKT2, SMAD4, EGFR and NFKB1, mostly in SW480 cells. Overexpression of miR-146a resulted in a partial cell cycle arrest in the both cell lines, while the apoptotic rate was also decreased. In regards to epithelial-mesenchymal transition factors, VIM was downregulated in the both cell lines, but SNAI1 was upregulated in Caco-2 cells. The wound closure assay showed a reduction in cell migration in SW480 cells, but an opposite effect was detected in Caco-2 cells following transfection with miR-146a mimic. Therefore, our results are indicating that overexpression of miR-146a, despite downregulation of oncogenic CXCR4, may not lead to a universal tumor suppressive effect in all CRC cells, and this is possibly due to differences in miR-146a effects on signaling pathways in each cell type. Selection of miR-146a for tumor suppression requires enough details regarding the signaling profile of cancer cells otherwise it may produce unexpected outcome.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  CXCR4; Colorectal cancer; EMT; Tumor-suppressor; miR-146a; miRNA mimic

Mesh:

Substances:

Year:  2021        PMID: 34601384     DOI: 10.1016/j.tice.2021.101654

Source DB:  PubMed          Journal:  Tissue Cell        ISSN: 0040-8166            Impact factor:   2.466


  1 in total

Review 1.  Recent Advances in CXCL12/CXCR4 Antagonists and Nano-Based Drug Delivery Systems for Cancer Therapy.

Authors:  Ruogang Zhao; Jianhao Liu; Zhaohuan Li; Wenhui Zhang; Feng Wang; Bo Zhang
Journal:  Pharmaceutics       Date:  2022-07-25       Impact factor: 6.525

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.